Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C
- Author:
Jong Han LEE
1
;
Jooyoung CHO
;
Juwon KIM
;
Young UH
;
Kap Jun YOUN
Author Information
- Publication Type:Original Article
- Keywords: Liver fibrosis; Hepatitis B; Hepatitis C; Fibroscan; Noninvasive marker
- MeSH: Area Under Curve; Bilirubin; Biomarkers; Blood Platelets; Cholesterol; DNA; Elasticity Imaging Techniques; Fibrosis; Hepatitis B; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Hepatitis; Hepatitis, Chronic; Humans; International Normalized Ratio; Liver Cirrhosis; Liver Diseases; Liver; Lymphocytes; Mean Platelet Volume; Neutrophils; Platelet Count; Prospective Studies; Prothrombin Time; Retrospective Studies; Risk Factors; Transferases; Triglycerides
- From:Laboratory Medicine Online 2019;9(3):153-160
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review of clinicopathological data. METHODS: We recruited 278 chronic hepatitis B patients who underwent Fibroscan and HBV DNA testing. A total of 115 HBeAg-positive and 159 HBeAg-negative chronic hepatitis B patients were analyzed. A total of 100 hepatitis C patients were analyzed. Successful fibroscan data, gamma-glutamyl transferase (GGT) to platelet ratio (GPR), platelet count, AST, ALT, international normalized ratio of prothrombin time, total cholesterol, triglycerides, bilirubin, mean platelet volume, AST to platelet ratio index, fibrosis index based on four factors (FIB-4), neutrophil to lymphocyte ratio (NLR), and NLR to platelet ratio were analyzed to determine the new noninvasive markers for assessing liver fibrosis. RESULTS: Elevated GPR (OR=9.1, P=0.011) and FIB-4 (OR=2.3, P=0.01) were associated with greater risk of liver fibrosis in chronic hepatitis B patients. FIB-4 (OR=6.04, P=0.005) was a risk factor for liver fibrosis in HBeAg-positive patients. FIB-4 (OR=2.371, P=0.015) and GPR (OR=33.78, P=0.003) were liver fibrosis risk factor in HBeAg-negative patients. In chronic hepatitis C patients, GGT (OR=1.033, P=0.002), triglyceride (OR=−0.990, P=0.038) and FIB-4 (OR=3.499, P=0.006) showed statistical significances. The AUCs were 0.816 in FIB-4 (P<0.001) and 0.849 in GPR (P<0.001). CONCLUSIONS: FIB-4 and GPR may be useful blood markers for assessing liver fibrosis in chronic hepatitis B and hepatitis C patients. Further well-designed prospective study is required to validate these noninvasive blood markers in clinical practice.
